Current Role of Functional Imaging in the Management of Lymphoma

Bruce D. Cheson[1] · Michel Meignan[2]

Abstract

Purpose of Review Functional imaging with 18FDG-PET-CT has transformed the staging and response assessment of patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Herein, we review the current role and future directions for functional imaging in the management of patients with lymphoma.

Recent Findings Because of its increased sensitivity, PET-CT is the preferred modality for staging of FDG-avid lymphomas. It appears to have a role for interim assessment in patients with HL with adaptive strategies that reduce toxicity in lower risk patients and increase efficacy in those at high risk. Such a role has yet to be demonstrated in other histologies. FDG-PET-CT is also the gold standard for response assessment posttreatment. Newer uses include assessment of total metabolic tumor volume and radiomics in pretreatment prognosis.

Summary Whereas PET-CT is more sensitive than other current modalities for staging and response assessment, the future of PET-CT will be in conjunction with other modalities, notably assessment of minimal residual disease and microenvironmental markers to develop risk adaptive strategies to improve the outcome of patients with lymphoma.

Keywords PET-CT · Lymphoma · Metabolic tumor volume · Imaging

Introduction

For more than a half century, functional imaging has been used in the management of patients with lymphoma, from staging prior to treatment to interim evaluation, and posttreatment assessment. Standardization of staging and response assessment permit comparisons among studies and facilitate regulatory approval. Newer applications of imaging include assignment of prognosis and risk adapted approaches. Taken together, functional imaging has contributed to the improved management of patients with lymphomas.

✉ Bruce D. Cheson
   bdcheson@gmail.com

1 Lymphoma Research Foundation, Wall Street Plaza, 88 Pine Street – Suite 2400, New York, NY 10005, USA

2 LYSA Imaging, Henri Mondor University Hospitals, University Paris Est, Créteil, France

Staging

Staging of lymphoma is necessary to define the extent of the disease to direct appropriate therapy. Early staging recommendations for lymphoma were primarily for Hodgkin lymphoma for which the primary mode of treatment was radiation therapy [1, 2]. At the time, effective treatments were nonexistent for other lymphoma histologies. Methodologies used to determine the extent of spread of disease ranged from staging laparotomy to imaging techniques including roentgenograms, intravenous pyelograms, lymphangiograms, and ultrasound. However, these modalities lacked sensitivity and were limited in their ability to distinguish active tumor from scar tissue, fibrosis, or other benign entities. Functional imaging was needed to fulfill this necessary objective.

The most successful of the early methods utilized gallium-67 (^{67}Ga) scintigraphy which relies on the accumulation of ^{67}Ga by viable lymphoma cells by binding to transferrin receptors. ^{67}Ga scans were more specific than CT scans in their ability to distinguish benign tissue from lymphoma with an accuracy ranging from 70 to 84%. The negative predictive value ranged widely from 65 to 96%. Unfortunately, ^{67}Ga scintigraphy suffered from numerous

deficiencies, which limited widespread adoption. Up to 7–14 days are required following injection of the isotope, before the results are available, which reduced its clinical utility. [67]Ga scintigraphy also suffered from low spatial resolution and suboptimal sensitivity and specificity. This issue was particularly notable for indolent lymphomas, and for bowel involvement, where interpretation could be confounded by physiological bowel uptake.

The next milestone came from the Costwold meeting which recommended inclusion of CT scans primarily for staging of Hodgkin lymphoma [3]. However, it wasn't until 1999 that the first widely accepted response criteria were published by the International Working Group which were based on the use of CT scans in the assessment of patients with non-Hodgkin lymphoma, but which were also adopted for Hodgkin lymphoma [4]. These guidelines standardized the definitions of complete remission (CR), complete remission unconfirmed (CRu), partial response (PR), stable (SD), and progressive disease (PD). However, these criteria were subject to intraobserver variation and were based on outdated methods of evaluation such as physical examination, chest radiographs, CT scans and ^{67}Ga scintigraphy.

PET Scanning

The first positron emission tomography (PET) scan was developed in 1973 by Hoffman and Phelps but was not applied to lymphoma for almost 20 years. In 1998 Townsend and Nutt invented the PET-CT scan using 2'-fluorodeoxyglucose (FDG). FDG uptake by malignant cells depends on the expression of the glucose 1–7 transporters (GLUT1 to GLUT7) and the rate of uptake depends upon the glycolytic activity, mainly the hexokinase II activity [5]. Non-malignant cells with high glycolytic activity, such as activated macrophages or immunocompetent cells, can similarly contribute to FDG uptake. Therefore, the uptake observed in lymphoma can not only be due to lymphoma, but also to microenvironment cells. Interpretation of a lesion's uptake on a PET scan performed at staging or for response assessment should therefore be interpreted in context of these two components [6]. Notably, in Hodgkin lymphoma, Hodgkin and Reed Sternberg cells (HRS) account for less than 1–5% of the total lymphoma but interact with the overwhelming population of non-neoplastic mononuclear bystander cells. These cells (CCR4-expressing cell subsets, including eosinophils, histiocytes, macrophages, plasma cells, and Th2 and Treg lymphocytes) are recruited by chemokines produced by the HRS cells and induce the expression of antiapoptotic proteins in HRS cells and their immortalization via a paracrine loop. There is an intimate relationship between the HRS cells and reactive cells of the microenvironment that enables the tumor to thrive and evade immune surveillance. The microenvironment is the major component of Hodgkin

lymphoma nodes. In addition, the uptake of FDG by the different components of the Hodgkin tumor has different prognostic meanings and behaves differently during treatment. GLUT1 expression in HRS cells correlates with PDL1 and PDL2 expression, but not with PD1 expression in the microenvironment [7].

Differences in glucose transport have been recently shown among the various lymphoma subtypes: GLUT1 and GLUT3 GLUT7 expression are involved in FDG uptake in DLBCL cells lines. GLUT7 is not involved in NK/T cells lines [8]. Clinically, FDG avidity is greater with aggressive than indolent subtypes, but with great variations within the histologies [9], the uptake by the environmental cells, the distribution of lesions (diffuse or focal the latter being easier to detect than a diffuse infiltration), and the localization of the lesion involving a parenchyma without (lymph node) or with physiological uptake (gut or bone marrow). As an example, bone marrow infiltration of follicular lymphoma is missed in 60% of cases which is explained by its diffuse character and may be missed in DLBCL when it is diffuse and not focal. The detectability of MALT lymphoma is a challenge due to the high physiological uptake in the gut as is the detection of other extra-nodal MZL. Thus, PET has proven to be useful in the majority of lymphoma histologic subtypes, with the exception of chronic lymphocytic leukemia/small lymphocytic lymphoma, extra nodal marginal zone lymphoma, and some cutaneous and enteropathy-type T-cell lymphomas.

PET Quantification

PET quantification is currently performed using the standardized uptake value (SUV), an indirect evaluation of FDG uptake and glucose utilization: The SUV is a semiquantitative ratio of the relative local increase of the FDG metabolism in a region of the body (e.g., a lymph node). This ratio would be equal to 1 if the FDG distribution were homogeneous throughout the body. However, the SUV in lymphoma lesions is markedly increased with the improvement of PET performances quite doubling in some histologies, preventing a comparison between newer data and older studies.

Since the degree of uptake measured by the maximum standardized uptake value (SUVmax) observed in a patient correlates with lymphoma aggressiveness, studies have suggested that an SUVmax of 14 or more found in an indolent lymphoma is suggestive of aggressive transformation [10]. This conclusion has been recently challenged in follicular lymphoma in which a high pretreatment SUV did not correlate with the presence of histologic transformation [11]. Moreover, the threshold proposed for transformation in older series must be reconsidered when comparing with the newer PET devices.

The Role of PET in Lymphoma Staging

The first attempt at a uniform staging system was the Rye Classification of 1966 [1] which was eventually supplanted by the Ann Arbor Classification of 1971 [2]. These were used primarily for HL as there were no successful treatments for NHL at that time. The Rye Classification divided patients into 4 stages on the basis of extent of disease, and into A and B related to the absence or presence, respectively, of constitutional symptoms. However, over the ensuing years, it became apparent that patients are better distinguished into limited stage (AA I and II) and advanced stage (bulky II, III, and IV) based on how they are treated and their expected outcome with therapy. More recently, however, numerous studies have demonstrated that PET-CT is more sensitive and specific than CT alone in staging for both nodal and extranodal disease [12–15, 16•]. Compared with CT, PET-CT identifies additional sites of disease leading to upstaging in 10–30% of patients, and, less so, rules out disease involvement in fewer cases. However, the data on change in management on the basis of PET-CT are limited with few data supporting that patient outcome is improved. In one of the largest studies, the RATHL trial in 1214 patients with advanced stage Hodgkin lymphoma, contrast enhanced CT, and PET-CT were compared in staging [17]. The two modalities were concordant in 80%; however, PET-CT upstaged 14% and downstaged 6% of patients. CT identified disease in only 7 patients who were negative by PET-CT. Thus, one of the most significant changes in staging as a result of PET-CT is the elimination of the need for bone marrow biopsies in most patients with Hodgkin and diffuse large B-cell lymphoma [18].

The Lugano classification [19] established PET-CT as the standard for staging FDG-avid lymphomas, not only because of its high sensitivity and sensitivity, but also to provide a baseline against which to compare posttreatment assessment. A contrast enhanced CT is only needed for accurate measurement of the size of nodes or masses. The increased sensitivity of PET-CT is of particular importance in identifying patients with limited disease who are being considered candidates for radiation therapy.

The Role of PET in Response Assessment

Numerous studies have demonstrated that PET and later PET-CT are more sensitive and specific than other imaging techniques for the evaluation of response in patients with various histologies of lymphoma. In 2005, Juweid et al. [20] reported that the outcome of patients with DLBCL and a residual mass that was no longer FDG-avid was similar to those with a CT confirmed CR. With the increased use of [18]-Fluorodeoxyglucose (PET) scanning, revised criteria were published by the NCI-Working Group, originally for Hodgkin and DLBCL [21]. Again, these were rapidly adopted, and their use expanded for other FDG-avid lymphomas.

Following publication of the revised guidelines, several events warranted further revisions. First, greater experience using the criteria identified issues needing clarification. Whereas the revised criteria used visual interpretation of PET scans, the development of the 5-point Deauville scale allowed for better standardization and interobserver concurrence. PET is positive if the residual uptake is higher than a fixed reference background (RB). This RB ranked in increasing intensity is the nearby background the mediastinal blood pool and the liver. For the same residual uptake, increasing the RB turns a PET positive to a negative.

In 2009 the Deauville criteria (DC) defined a set of visual criteria dedicated for interim PET evaluation and scaling the residual uptake against all these reference background on a 5-point scale. DC underlined that the liver was the RB visually easier to evaluate. A score of 4 (moderately increased uptake over the liver) and 5 (markedly increased uptake and/or new lesion) was claimed positive**.** These criteria have improved readings of interim PET in HL [22] and DLBCL [23]. However, there are difficulties in visual reporting since the eye is more sensitive to contrast than to differences of intensities. The uptake of a node surrounded by a faint background (e.g., an axillary lymph node) may seem more intense and can mislead the analysis.

The Deauville criteria were then redefined in Menton [24] and, subsequently, in Lugano in 2014 [19, 25] and extended from interim to end of treatment PET. Score 5 was defined to be an uptake > 2–3 times the SUVmax in normal liver. However, although it was advised to report the PET using a SUV scale, the term "moderately increase" of score 4 was not defined. Thus, scoring 4 based on a small increase of SUV relative to the liver may result in a false positive result.

Quantitative Approaches

A quantitative approach has been proposed several years ago in DLBCL to overcome the difficulties in the interpretation of the DS: i.e., the ΔSUVmax, the reduction of the SUVmax from baseline to interim [26]. For iPET the cutoff for better discrimination of response was a reduction of 66% after two cycles and 72% after 4 cycles. Several retrospective and prospective studies performed by national lymphoma groups (LYSA, CALBG/ALLIANCE, SAKK) have reported that this approach performed better than DS for predicting outcome in aggressive DLBCL with a better interobserver reproducibility [23, 27, 28••, 29•, 30, 31]. Another approach has been proposed for all risk categories of DLBCL: a tumor/liver (T/L) ratio of 1.4. It was the only significant factor for outcome prediction at iPET4 and EOT in a series of 181 patients [32]. In the AHL 2011 trial

including 800 advanced HL patients, the PET-guided strategy of de-escalation from BEACOPP to ABVD was based on PET negativity, but PET positivity was considered if the T/L was ≥ 1.4 [33]. The 5-year PFS was remarkably high 85% and similar in the standard and the PET-driven arms. The overall survival was also similar and higher than 95%.

Additional data supported the validity of PET in other histologies, notably follicular lymphoma. Trotman et al. performed a pooled analysis of two retrospective and one prospective study and demonstrated that posttreatment PET predicted not only PFS, but also OS when a cut-off of DS4 was used [34]. In 2012 at a conference at the International Workshop on Malignant Lymphoma (Lugano, Switzerland), the need for revised guidelines for evaluation, staging, and response assessment were discussed and developed over the ensuing years. They were eventually published in 2014 as the Lugano classification [19]. Revisions included a modification of the Ann Arbor Classification for staging, FDG-PET-CT in the staging and response assessment of all FDG-avid lymphomas, and elimination of the need for bone marrow evaluation in the staging of Hodgkin and DLBCL unless it was likely to alter treatment. Residual masses that were no longer FDG-avid were still consistent with a complete metabolic response. However, progression of a single node or mass indicated PD.

New Staging and Response Techniques

Baseline PET provides the whole tumor burden. In addition, several additional parameters can be extracted by a mathematical process called image segmentation to improve on the prognostic value of the scan. Among these parameters, the total metabolic tumor volume (TMTV) is the most investigated. TMTV is the sum of the 3D measurements of the volume of each lesion with FDG uptake; it is the viable fraction of tumors and microenvironment. The SUVmax has been addressed before, with its limits as an absolute value. For the same reason, this limit also applies to the total lesion glycolysis which is the sum of the SUV of all the element (voxel) included in the metabolic volume. Other metrics exist for single lesion under the word of radiomics; but they all depend on the method of metabolic volume measurement as detailed below. Metabolic volume cannot be drawn visually but must be determined by computer thresholding. The thresholding of the lesion volume is determined according to a relative reference which can be the SUVmax of the lesion (for instance, 40% of the tumor SUVmax, i.e., all the voxel between the SUVmax and 40% of the SUVmax are comprised in the volume) or any other internal reference; an absolute value of SUVmax such as 2.5 or 4 can also be chosen as a threshold (Fig. 1). Different methods resulted in different volumes depending on the SUV in the lesions. However, the same method used in similar population should result in similar median TMTV and different investigators


MTV= 120 cm^3 MTV= 1119 cm^3 MTV= 72 cm^3 MTV= 678 cm^3
SDmax= 0.20 m^{-1} SDmax= 0.09 m^{-1} SDmax= 0.38 m^{-1} SDmax= 0.44 m^{-1}

Low risk   Intermediate risk   High risk

Fig. 1 TMTV in 4 patients with DLBCL ranging from small (72cm^3) to large (1119 cm^3) volumes. TMTV has been computed with the % SUVmax thresholding method. In these patients, the maximum distance between lesions normalized by BSA, SDmax, has been computed. Patients with low risk of events have a small metabolic tumor volume ≤ 220 cm^3 and a small normalized maximum distance ≤ 0.32 m^{-1} between the lymphoma sites. Patients with high risk have a large volume and a high maximum distance. Patients with intermediate risk of events have either a large volume or a high distance. From (36●)

using the same method, but different software must find similar values.

TMTV is now automatized but requires standardization to be use in trials. This has been launched by cooperative groups in 2019 evaluating different methods and defining a benchmark in order that every group using the same software with the same technique of volume measurement must find the same TMTV median value. Recently artificial intelligence methods have been applied successfully to TMTV measurement, and this field is under investigation [35, 36•, 37].

Radiomics and Heterogeneity

In all published studies in aggressive B-cell lymphomas, TMTV stratified patients better than Ann Arbor Stage. Patients with similar stage may have markedly different TMTV, but TMTV and stage do not fully characterize the heterogeneity of the lesions or their dissemination.

Other radiomic features include metrics derived from measurements in the image. Two radiomics parameters describe the heterogeneity: the voxel value histogram, for instance, the SUV distribution in a bulk and the voxel value spatial arrangement which is the SUV spatial organization within this bulk. Ceriani et al. [38] measured the metabolic heterogeneity (MH) in 103 patients with primary mediastinal B-cell lymphoma (PMBL) using the voxel SUV histogram. They observed that the metabolic heterogeneity in the mass was predictive of outcome. Progression-free survival at 5 years was 94% vs 73% in low- vs high-MH groups. They proposed that total lymphoid glycolysis and MH could be used in future studies using risk-adapted strategies. Others have come to similar conclusions [39].

Interim Assessment

One of the more controversial areas of imaging is assessment during the planned treatment. Interim assessment has been suggested to potentially identify high-risk patients who are unlikely to respond to therapy, permitting an alteration in therapy to improve outcome, or, alternatively, those who are lower risk for whom the duration or intensity of therapy could be reduced, limiting toxicity.

A number of factors prevent the routine use of interim scanning. First, the optimal timing remains unclear. Residual activity on iPET can be highly variable with the number of cycles and the effect of residual tumor cells as well as treatment inflammatory or environmental cells. PET performed after cycles 1 and 2 evaluates chemosensitivity; however, it also records acute necrosis and inflammation. Results of PET performed after cycles 3 and 4 are balanced

by regrowth. Consequently, one must not mix data from 1 and 2 to 3 and 4 or try to derive what will be the results at 2 cycles from what observed at cycle 3. Some trials have explored in DLBCL the two steps of response by performing PET after 2 and 4 cycles which help stratify the patients [33, 40].

Benefit of interim PET has been most clearly demonstrated in Hodgkin lymphoma. Gallamini and coworkers first demonstrated that the results of a PET scan following 2 cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were more predictive of outcome than standard risk scoring systems [22, 41]. In the RAPID trial [42], patients with limited stage disease received 3 cycles of ABVD and then underwent PET-CT. Those who were negative were randomized to either involved field RT or no further therapy. Survival was similar in the two groups, demonstrating that more than 90% of patients can be spared unnecessary radiation. Subsequent analysis showed that the best discriminant was a DS of 5 [16•]. In the German HD15 study [43], patients received one of several induction regimens. Those without residual disease or ≤ 2.5 cm on CT and a negative PET received no further therapy. Those with a residual mass > 2.5 cm on CT and a negative PET were followed without further therapy. Those with a positive PET underwent radiation therapy. The investigators demonstrated that they were able to reduce the number of patients who underwent radiation therapy from 71% in earlier trials to 11% in the HD15 study with no compromise in efficacy. In the aforementioned RATHL study [17], patients with advanced disease received 2 cycles of ABVD followed by a PET-CT scan. Those with a negative PET-CT were randomized to 4 additional cycles of either ABVD or AVD. The outcome of the two groups was similar, but with less toxicity in the AVD group. Thus, these studies demonstrated a reduction in therapy and toxicity with an interim scan.

Based on studies by Gallamini and coworkers [22, 41], patients with advanced HL and a positive interim scan would be expected to have a long-term PFS of about 20–30%. In the RATHL trial [17], patients with a positive interim scan were randomized between 4 cycles of BEACOPP-14 or 3 of escalated BEACOPP followed by another PET scan. If the scan was negative, patients received 2 additional cycles of BEACOPP-14 or 1 of escalated BEACOPP with no radiation therapy. Those with a positive scan went on to salvage approaches. Results with the two regimens in PET-negative patients were similar with a PFS of 60–70%, far better than expected. Other risk-adapted studies from various groups have generated similar findings with PFS consistently in the 60–77% range. Thus, in high-risk patients, altering treatment appears to improve outcome. This observation has been confirmed in other studies [33, 44–48].

Unfortunately, benefit from interim PET has been difficult to demonstrate in patients with DLBCL [49]. The largest

randomized study was the PETAL trial in which patients with a positive interim scan after 2 cycles of R-CHOP were randomized to an intensive Burkitt-like regimen or to continue on induction R-CHOP for 4 additional cycles [28••]. There was no benefit from the aggressive regimen with respect to event-free or overall survival; however, those patients experienced greater toxicity. Similar results were reported in patients with peripheral T-cell lymphoma. Thus, interim PET should not be considered a standard approach in patients with aggressive lymphomas.

Assessing Response with Immunomodulatory Therapy

Recently, a number of immunomodulatory drugs in solid tumors as well as lymphoid malignancies have been found to induce a flare reaction. These findings on PET scan may be confused with PD resulting in discontinuation of a potentially active therapy. Representative drugs used in lymphomas include lenalidomide, rituximab, brentuximab vedotin, Bruton tyrosine kinase (BTK) inhibitors, and check point inhibitors. This observation led to the development of the LYRIC (lymphoma response to immunomodulatory therapy criteria) recommendations [50]. The working group identified 3 subtypes of indeterminate responses: IR1, increase in tumor volume within the first 12 weeks; IR2, increase in volume or number of lesions at any time, but not ≥ 50%; and IR3, an increase in FDG uptake without an increase in lesion size. A biopsy or subsequent scans will help distinguish flare from progressive disease. In addition, incorporation of next-generation sequencing assays, such as circulating tumor DNA, should enable better discrimination.

FDG-PET for Assessment of End of Treatment

End of treatment (EOT) was the first time point where the superiority of PET imaging over CT was demonstrated. Before the publication of harmonized criteria for PET reporting, several studies demonstrated the value of PET reported using self-made criteria to determine whether a residual mass after first-line chemotherapy in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas was persistent disease or non-malignant tissue. Juweid et al. summarizing in 2008 results obtained on 635 patients from different studies where PET was reported prior to harmonization of criteria noted that in HL the NPV was 71–100% with a PPV ranging from 13 to 100%; in NHL, the NPV was 74–100% and PPV ranged from 50 to 83%. These figures have changed with the DS, still confirming the high negative predictive value of end of treatment PET, but a PPV increase to 90% in HL, with PPV values ranging from 50 to 100% in DLBCL.

In the HD0607 trial including 276 patients with advanced stage (IIB-IVB) HL with a baseline nodal mass of ≥ 5 cm who were PET negative after 6 cycles of ABVD experienced a similar 6 year PFS whether (91%) or not (95%) the mass was irradiated [51••], supporting that radiation can be omitted in this population. In a recent British Columbia study, patients who were PET negative after 6 cycles of R-CHOP (72%) did not receive consolidation radiotherapy. Time to progression and overall survival at 3 years were 83% and 56%, respectively, for those with a negative scan and 87% and 64%, respectively, for those with a positive scan who received consolidative radiotherapy. Thus, radiation could be eliminated in PET negative patients with bulky disease ≥ 10 cm whose outcome was indistinguishable from those without bulk [52]. In DLBCL the PPV of end of treatment PET may be equivocal even when PET is performed a minimum of 3 weeks, but preferably 6 or 8 weeks after eoT as recommended [25]. This finding can be attributed either to inflammatory changes persisting after immunochemotherapy or to difficulties in scoring DC 4. Consequently, many centers in routine practice use biopsy in DLBCL, in case of persistent positive sites. In addition, if there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or a subsequent scan.

Several studies have shown that post-induction PET predicts outcome in FL [34]. Trotman et al. performed a pooled analysis of 3 trials; PRIMA, PET Folliculaire, and FOLLO-5. In the 3 trials, 439 patients underwent PET scan. Using a cut-off of 4 or higher on the DS as a positive study, the hazard ratio for PFS for those with a positive vs negative scan was 3.9 (95% CI 2.5–5.9, $p < 0.0001$) and was 6.7 (2.4–18.5; $p = 0.0002$) for overall survival. In contrast, CT-based response was only weakly predictive. FOLL12, including 769 patients treated with 6 cycles of R-CHOP or R-bendamustine + 2R, failed to demonstrate an advantage of PET- and MRD-guided therapy against standard R-maintenance. In contrast, patients with guided therapy and maintenance omitted had a 76% 3-year PFS versus 96% in standard arm [53]. An analysis of posttreatment PET was also performed from the GALLIUM trial [54] including 1202 patients of which 595 were included in the PET cohort interpreted prospectively by the IHP and 508 retrospectively by the Lugano classification. Following treatment, 65.5% achieved a mCMR by IHP and 75.6% by Lugano classification. The 2.5-year PFS from end of induction was 87.8% in CRs and 72% in non-CRs according to the IHP. Using the Lugano criteria, the PFS was similar for the CMRs at 87.4%, but was only 54.9% for the others. They concluded that their data validated the Lugano criteria and supported PET as preferred over contrast enhanced CT scan.

In addition, PET-CT obviates the need for a posttreatment bone marrow biopsy in both DLBCL and FL [55•].

Thus, PET-CT remains the standard for response assessment for FDG-avid lymphomas, and its performance will be improved with subsequent modifications of response criteria [19].

Surveillance

Another controversial role for PET scanning is as surveillance following posttreatment assessment. Theoretically, regular follow-up scans should identify recurrence sooner allowing for the rapid institution of salvage therapy and improved patient outcome. Unfortunately, there are no data to support this possibility. Moreover, false positives lead to additional scanning and invasing procedures, and the practice is not cost-effective. Thompson et al. [56] performed an analysis of 680 patients with DLBCL treated with anthracycline-based chemo-immunotherapy. Of these, 81% achieved a CR, of which 20% relapsed. Of the relapses, 64% were identified before a scheduled visit. Surveillance imaging identified asymptomatic relapse in 4 patients (1.8%). Clinical features at relapse included symptoms in approximately 60%, abnormal physical examination in 50%, elevated LDH in 50%, and with at least one feature in 90%. Importantly, the overall survival was the same with or without routine scans. Thus, the recommendation is not to perform surveillance imaging in DLBCL and HL in the absence of evidence of disease recurrence [19]. How best to manage patients with other histologies is less clear. In patients with FL and a CR, similar management appears to be acceptable. For those with residual disease following induction, CT scans can be performed every 3–6 months, depending on the size of the mass and its rate of growth. There are no specific recommendations for other histologies and patients should be managed according to best medical judgment.

PET for Pretreatment Prognosis

A number of imaging procedures have been shown to be prognostic prior to initiating lymphoma treatment. Total metabolic tumor volume (TMTV) obtained on a baseline PET-CT is an evaluation of the total metabolic tumor burden. TMTV has been shown to be a strong predictor of PFS and OS in several lymphoma subtypes. In DLBCL the TMTV is correlated to the circulating tumor DNA (Alig et al. in revision JCO 2020). The GOYA study, including 1418 DLBCL patients, found that baseline TMTV is prognostic for PFS and OS, the risk increasing with the volume quartile [57]. In high tumor burden follicular lymphoma, the FOLLCOL study including 181 patients has shown that baseline TMTV predicted, better than FLIPI and FLIPI2, PFS, POD24, and OS events [58]. In early stage Hodgkin lymphoma, the analysis of the standard arm of the H10 trial confirmed that a high baseline TMTV correlated with a lower PFS and OS. The 5-year estimates of PFS was 92% in the low TMTV group compared with 71% in the high TMTV group, 98% 5-year OS vs 83%. TMTV was superior on current EORTC/LYSA classification used in the trial (favorable/unfavorable). Indeed, two-thirds of patients classified as unfavorable were reclassified as low risk with TMTV. The high-risk patients identified with the TMTV had a 71% PFS instead of 84% for the unfavorable category [59]. Recently it has been shown that TMTV before CAR T-cell infusion was highly prognostic of early relapse and combined with extranodal involvement could stratify the risk of progression in a population of 116 relapsed refractory DLBCL patients [60].

In addition in several lymphoma subtypes (DLBCL, PTCL,HL, FL, PMBL), TMTV combined with other prognostic indices better stratifies the risk than the clinical indices alone [61–63] [58, 64] and that combined with molecular profile it can identify in low molecular risk patients a subset of patients with poor outcome [65].

Using an approach which combines TMTV and a clinical parameter, a simple prognostic index has been built associating TMTV and ECOG in DLBCL [60, 66]. This index was obtained from patients 60–80 years old in the REMARC trial in good response after R-CHOP. Patients between 60 and 80 with ECOG $\geq$ 2 and TMTV > 220 at baseline, before R-CHOP, had a worse prognosis and could be defined as ultra-high risk. This index which is more discriminating than IPI or NCCN-IPI has been validated in 2306 DLBCL patients from two prospective trials, PETAL and GOYA, and a group of real-world patients from the UK, France, Poland, and Portugal [60].

Different TMTV cut-offs appear to separate high- and low-risk patients which has created confusion. The likely explanation is that there are several issues inherent to the measurement method. The problem becomes simpler for the cut-off once the method is decided. As perfectly described by Pfreundschuh, taking the size of the bulk as an example, the best cut-off to separate high- and low-risk patients depends on the level of risk in the population [67]. Therefore, the TMTV cut-off changes with the type of population, and for a given population, it differs between methods.

Consequently, it has been shown that all methods used in the same population of DLBCL give KM curves with similar PFS and OS. TMTV is a strong prognostic tool, very soon available in routine but has never been used yet to guide a therapeutic strategy. TMTV is prognostic but at this time only one study in HL showed its predictive value (Moskowicz et al., Blood 2017). Indeed, in relapsed or refractory HL patients, TMTV improved the predictive power of pre-ASCT PET. In this study, baseline TMTV and pre-ASCT PET were independently prognostic: 3-year EFS for pre-ASCT PET-positive patients with low TMTV was 86%.

Integration of PET into Other Modalities

Direct comparison of unenhanced lower-dose PET-CT and cePET-CT suggests that although ceCT may occasionally identify additional findings and improve detection of abdominal or pelvic disease, management is rarely altered by ceCT in FDG avid lymphoma. Contrast-enhanced CT when included in staging/restaging should ideally be performed at a single visit combined with PET-CT, if not already performed, starting with the PET/CT before injecting contrast media to avoid errors in quantitative PET parameter measurements.

Metser et al. [68] assessed the role of PET/CT, using a multicenter registry including 850 participants based on clinical data and CT, or equivocal CT for advanced stage, who were considered for curative-intent first-line therapy compared to an historical control pool staged by contrast enhanced CT. There was a lower 1-year mortality for participants with advanced non-Hodgkin lymphoma in the PET/CT versus CT cohort and for those with limited stage at PET/CT compared with those with limited stage at CT. PET/CT helped to upstage approximately 18% of participants and planned management was frequently altered. Participants with aggressive non-Hodgkin lymphoma whose first-line therapy was guided by PET/CT had significantly better survival compared with participants whose treatment was guided by CT alone.

PET/MRI

PET combined with MRI has been introduced recently and seems to give comparable results compared to PET/CT in pediatric lymphoma with the advantage of a decrease of radiation dose [69]. Whereas PET-MRI might be of interest to evaluate brain and spinal cord lesions, the SUV is modified due to the process of attenuation correction and consequently so is the PET quantification. Until now, no published systematic and prospective studies demonstrate the advantages of PET/MRI over PET/CT in lymphoma management in adults.

PET for Assessment of the Microenvironment

The role of microenvironment on FDG uptake is important in Hodgkin lymphoma as described above. Agostinelli et al. [70] showed that increased expression of CD68 macrophages and PD1 by microenvironmental cells was associated with an unfavorable prognostic value permitting stratification of patients with a negative interim PET-2 scan. Indeed, in a group of 208 patients, a subset of PET-2-negative patients with a 3-year PFS significantly lower than that of the remaining PET-2-negative population was identified. Viviani et al. [71] also showed that elevated levels of serum thymus and activation-regulated chemokine (TARC) identifies among PET-2-negative patients those with a worse prognosis.

The importance of the microenvironment also explains the so-called pseudo-progression observed after immunomodulatory drugs such as check point inhibitors or after CAR-T cell therapy. The phenomenon is associated with a transient increase in tumor size and activity secondary to an augmented immune infiltrate. Rather than a real progression, pseudo-progression represents a flare phenomenon induced by the massive recruitment of immune cells into the tumor microenvironment. It is a transitory event, confirmed as such, only during subsequent scanning (or in the case of biopsy), demonstrating indeed tumor regression and treatment benefit. Lymphoma response to immunomodulatory therapy criteria (LYRIC) classified the patterns of flare reactions under the category of indeterminate response (IR), with 3 subcategories: IR1, increase in overall tumor burden; IR2, appearance of new lesions or growth of 1 or more existing lesions; and IR3, increase in FDG uptake of 1 or more lesions without a concomitant increase in lesion size or number. Importantly, the authors also proposed to consider that an increase of FDG avidity of 1 or more lesions suggestive of lymphoma without a concomitant increase in size of those lesions meeting progressive disease (PD) criteria does not constitute PD [50]. Recently a retrospective study of 45 R/R HL patients has shown that early CT and PET/CT at a median of 2 months after initiation of nivolumab predicted overall survival in relapsed or refractory Hodgkin lymphoma using Lugano 2014 or LYRIC criteria and that early PET detected additional patients with complete metabolic response [72]. However, they did not observe any instances of pseudoprogression. This observation confirmed a previous analysis of the PET response in these conditions [73].

PET and Minimal Residual Disease

Despite the achievement of a CMR, patients with lymphoma frequently relapse, reflecting the level of sensitivity of the assay. Several studies in FL support the integration of measures of MRD into response assessment [74]. The GALLIUM trial compared rituximab with obinutuzumab combined with chemotherapy in untreated FL [75]. Despite similar response rates between the cohorts, there was a modest but significant difference in PFS. Similarly in the GADOLIN study comparing bendamustine plus obinutuzumab versus bendamustine alone in rituximab refractory follicular and low-grade NHL [76], overall and complete response rates were comparable, yet the combination achieved longer PFS and overall

Table 1 Current role of FDG-PET-CT in clinical practice*

Time point	Hodgkin lymphoma	Diffuse large B-cell lymphoma	Follicular lymphoma	Other FDG-avid histologies (e.g., indolent NHL, MCL)
Staging	Yes	Yes	Yes	Yes
Interim	Yes — Can reduce therapy in low-risk patients and improve outcome in high-risk patients	No — No evidence for improving outcome using DS; however, need further study using ΔSUV	No — No data	No—No data
Posttreatment/re-staging	Yes	Yes	Yes	Yes
Surveillance	No — Unlikely to detect asymptomatic relapse	No — Unlikely to detect asymptomatic relapse	No — No data	No—No data

*Use in clinical trials may vary according to study question and clinical endpoints

survival. The improvement in outcome was associated with a greater and more prolonged reduction in MRD [77].

Future Directions

Prognosis

Whereas PET-CT has been shown to provide accurate staging and response information, several lines of evidence support its role in pretreatment prognosis. One of the more exciting possibilities would be to combine baseline TMTV with other assays to develop risk adapted strategies. Kurtz et al. [78] demonstrated that dynamic measurements of ctDNA in 217 DLBCL patients could be complemented by results of interim PET. A good correlation was also found between baseline ctDNA and TMTV by this group [79]. However, TMTV does not translate the spread of the lesion which is in part expressed by Ann Arbor classification. Recently a new index the normalized maximum distance existing between two lymphoma lesions has been described as prognostic of outcome in a series of 95 DLBCL patients from the LNH073B trial [80]. This index has been validated in 290 DLBCL patients of the REMARC trial and reported highly prognostic of PFS. Combined with TMTV, it identifies a very high-risk category, these two adverse factors seeming more present in patients with CNS relapses [36•]. Interesting results from radiomics came from a recent retrospective study on HL patients where a model developed a posteriori based on the radiomic characteristics of the bulky mass appeared to predict refractory disease [81]. Other potential combination strategies have been suggested, including radiomics and molecular genetic signatures [82].

New Tracers

Several new tracers have been evaluated to improve on FDG. F18 deoxy-fluoro-thymidine (FLT) which has no brain uptake was an interesting tool to detect brain involvement;

but it is not readily available and is expensive. Studies have shown that early FLT has a lower positive predictive value than FDG in DLBCL [83]. F18 Glutamine analog, proposed to obviate the risk of false-negative response with FDG when tumor is growing mainly through glutamine uptake, has not yet been assessed in a large series of lymphoma patients, and the first results in solid tumors were disappointing except in glioblastoma [84]. ^{89}Zr-immuno-PET is a promising noninvasive clinical tool that measures target engagement of monoclonal antibodies (mAbs) to predict toxicity in normal tissues and efficacy in tumors. First clinical results showed that nonspecific uptake of mAbs for tissues without target expression can be quantified using ^{89}Zr-immuno-PET at multiple time points [85]. Other interesting tracers under investigation include F18 Fludarabine, which could have a better predictive positive value than FDG [86], and Ga68 Pentixafor labeling CXCR4 expression which has been used to explore CNS lesions and MALT lymphoma [87]. None of these tracers are currently clinically available.

Use of PET-CT in Clinical Practice and Clinical Trials

Despite the marked contribution of PET-CT to the management of patients with lymphoma, the use of this modality should be limited to appropriate indications (Table 1). The decision whether to use PET-CT should be determined by the clinical situation, e.g., clinical practice vs clinical trial. PET-CT is preferred for the staging of all FDG-avid histologies given its improved sensitivity and specificity compared with CT alone. The benefit of interim scans has only been demonstrated in HL to assist in improving efficacy for high-risk patients and reducing toxicity for those at low risk. PET-CT is also preferred for restaging after treatment of lymphoma that were FDG-avid prior to therapy. Subsequent PET-CT should only be considered in the setting of suspicion of recurrence on a CT scan, in case of clinical features of relapse if CT is negative, and to identify the preferred

lesion for a biopsy. The limited use of unnecessary scans reduces expense, radiation exposure, and potential for false positive results. In contrast, the use of PET-CT in clinical trials not only includes those indication noted for clinical practice, but also to address clinically important study questions and to confirm suspicious findings on follow-up CT scans being used to assess PFS. The concomitant use of a contrast enhanced CT scan with the PET should be limited to situations where measurement of the size of nodes or masses is important in patient management.

Interpretation and Revised criteria

Two important tasks must be now accomplished. First, an international committee is working on simplifying and standardizing TMTV [88]. Second, the Deauville criteria must be better defined, especially score 4. Indeed, the UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL) and showed that only score 5 at interim was predictive of PFS [89], and, in limited disease, the threshold for score 5 has to be increased [16•]. Precision must be added to Lugano classification for other lymphomas such as follicular lymphoma and the role of delta SUV [40, 90]. Finally, integration of PET-CT with other modalities will lead to improved assessment and management of patients with lymphoma.

Conclusions

Metabolic imaging with PET-CT has improved the accurate staging and response assessment of patients with lymphoma. It also enables risk adapted strategies, notably in HL, to reduce toxicities in low-risk patients while improving outcome for those at high risk. To date, the same observations have not been made in other histologies. Pre-treatment PET-CT has been shown to be prognostic, especially when using TMTV and other measures of radiomics. Moreover, PET-CT is being integrated with other modalities such as assessment of minimal residual disease and microenvironmental factors, which will lead to therapeutic approaches that will improve the outcome of patients with lymphoma.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Rosenberg SA. Report of the committee on the staging of Hodgkin's disease. Cancer Res. 1966;26:1310.
2. Rosenberg SA, Boiron M, DeVita VT Jr, et al. Report of the committee on Hodgkin's disease staging procedures. Cancer Res. 1971;31:1862–3.
3. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol. 1989;7:1630–6.
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244–53.
5. Meignan M, Itti E, Gallamini A, Younes A. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015;42(4):623–33.
6. Meignan M. Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells. Eur J Nucl Med Mol Imaging. 2014;41(9):1732–4.
7. Koh YW, Han JH, Park SY, Yoon DH, Suh C, Huh J. GLUT1 as a prognostic factor for classical Hodgkin's lymphoma: correlation with PD-L1 and PD-L2 expression. J Pathol Transl Med. 2017;51(2):152–8.
8. Liu YM, Zhai XM, Wu YW. Biological correlation between glucose transporters, Ki-67 and 2-deoxy-2-[18F]-fluoro-D-glucose uptake in diffuse large B-cell lymphoma and natural killer/T-cell lymphoma. Genet Mol Res. 2016;15(2).
9. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
10. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of [18]fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643–51.
11. Mir F, Barrington SF, Brown H, Nielsen T, Sahin D, Meignan M, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020;135(15):1214–8.
12. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altenhoefer C, Finke J, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer. 2001;91:889–99.
13. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, et al. Is CT scan still necessary for staging in Hodgkin and nonHodgkin lymphoma patients in the PET/CT era? Ann Oncol. 2006;17:117–22.
14. Wirth A, Foo M, Seymour JF, Macmanus MP, Hicks RJ. Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2008;71:213–9.
15. Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood. 2016;127(12):1531–8.
16.• Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study. J Clin Oncol. 2019;37(20):1732–41 **Of importance: In the RAPID trial, patients with early stage HL and a negative PET (Deauville score 1-2) after 3 cycles of ABVD were randomized to involved field radiation or no further**

therapy, whilst those with a positive scan (Deauville score 3-5) received a fourth cycle of chemotherapy and radiation. The investigators found that only a Deauville score of 5 carried an inferior prognosis, not just a positive scan.

17. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. New Engl J Med. 2016;374:2419–29.

18. Cheson BD. Hodgkin lymphoma: protecting the victims of our success. J Clin Oncol. 2012;30(36):4456–7.

19. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma - the Lugano classification. J Clin Oncol. 2014;32:3059–68.

20. Juweid M, Wiseman GA, Vose JM, Ritchie JM, Menda J, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol. 2005;23:4652–61.

21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Horning SJ, Coiffier B, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

22. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scanle. Haematologica. 2014;99:1107–13.

23. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Véra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312–20.

24. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014;55(1):31–7.

25. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Muller S, et al. The role of imaging in the staging and response assessment of lymphoma: consensus of the ICML Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

26. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.

27. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37–43.

28.•• Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024–34 **Of Outstanding Importance: In the PETAL trial, patients with aggressive B- or T-cell NHL were treated with two cycles of standard chemo- or chemo-immunotherapy and underwent an interim PET-CT scan. Those with a positive scan were randomized to either continue the same treatment of to receive more intensive therapy. In this, the first prospective trial of reacting to an interim PET scan, there was no benefit, but increased toxicity, from modifying therapy. Thus, there currently is no role for interim scans in patients with these histologies.**

29.• Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020;135(25):2224–34 **Of Importance: In this substudy of the randomized comparison of R-CHOP vs dose adjusted R-EPOCH in patients with newly diagnosed DLBCL, interim PET-CT was performed and correlated with outcome. Whereas visual assessment did not predict outcome, there was a correlation between the reduction in Δ SUV and overall survival which may have implications for future risk-adapted studies.**

30. Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, et al. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. Hematol Oncol. 2020;38(5):715–25.

31. Meignan M, Gallamini A. ΔSUVmax for interim PET in DLBCL: old is new. Blood. 2020;135(25):2202–3.

32. Toledano MN, Vera P, Tilly H, Jardin F, Becker S. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor/liver ratio. PLoS One. 2019;14(2):e0211649.

33. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–15.

34. Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. PET-CT after front-line rituximab-chemotherapy is highly predictive of survival in follicular lymphoma: a pooled analysis of central scan review in three multi-centre studies. Lancet Hematol. 2014;1:e17-27.

35. Capobianco N, Meignan M, Cottereau AS, Vercellino L, Sibille L, Spottiswoode B, et al. Deep-learning (18)F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med. 2021;62(1):30–6.

36.• Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(†). Ann Oncol. 2020 **Of Importance: Although pre-treatment PET-CT predicts outcome in patients with DLBCL, newer approaches may improve on this procedure. In this analysis from the REMARC trial, the authors demonstrate that the largest distance between two lesions was highly prognostic, independent of the TMTV, and improving patient risk stratification**

37. Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2020.

38. Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018;132(2):179–86.

39. Meignan M, Cottereau AS. FDG-PET in PMBCL: which heterogeneity? Blood. 2018;132(2):117–8.

40. Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315–26.

41. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior

to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–52.

42. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therpy for early-stage Hodgkin's lymphoma. New Engl J Med. 2015;372:1598–607.

43. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

44. Gallamini A, Rossi A, Patti C, Picardi M, Di Raimondo F, Cantonetti M, et al. Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial. Hematol Oncol. 2015;33(suppl 1):163–4.

45. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorode-oxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016;34:2020–7.

46. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34:1375–85.

47. Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132(10):1013–21.

48. André MPE, Girinski T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35:1786–94.

49. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.

50. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489–96.

51.•• Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 Trial. J Clin Oncol. 2020;38(33):3905–13 **Of Outstanding Importance: The standard approach for patients with advanced HL and a large pretreatment mass has been 6 cycles of chemotherapy followed by radiation. In this risk-adapted trial, patients with a negative scan after 2 and 6 cycles were randomized to consolidative radiation therapy or no further treatment. The results demonstrated that radiation could be safely omitted, regardless of the size of the pretreatment mass.**

52. Freeman CL, Savage KJ, Villa D, Scott DW, Srour L, Gerrie AS, et al. Long-term results of PET-guided radiation in advanced-stage diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2020.

53 Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, et al. Response oriente4d maintenance therpy in avanced follicular lymphoma. Results of the interim analysis of the FOLLO 12 trial conducted by the Fondazione Italiana Linfomi. Hematol Oncol. 2019;37:153–4.

54. Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530–42.

55.• Rutherford SC, Herold M, Hiddemann W, Kostakoglu L, Marcus R, Martelli M, et al. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood Adv. 2020;4(8):1589–93 **Of Importance: For patients with FL or DLBCL with bone marrow involvement prior to treatment, standard restaging has included a repeat bone marrow biopsy. For patients in the GALLIUM trial in FL and the Goya trial in DLBCL with a complete remission posttreatment, repeat bone marrow biopsy added little to the management of the FL patients, but had a small merit for those with DLBCL. Data from other studies using PET fail to show benefit for a repeat biopsy even in DLBCL.**

56. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506–12.

57. Kostakoglu L, Martelli M, Sehn LH, Belanda D, Carella AM, Chua N, et al. Baseline PET-derived metabolic tumor volume metrics predic t progression-free and overall survival in DLBCL after first-line treatment> results from ther phase 3 GOYA study. Blood. 2017;130:abstraxt 824.

58. Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618–26.

59. Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood. 2018;131(22):2449–53.

60. Vercellino L, Cottereau A-S, Casasnova RO, al. e. High total metabolic tumor volume at baseline allows discrimination of survival even in patients responding to R-CHOP. Blood. 2020:in press.

61. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.

62. Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, Bonnet C, et al. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. J Nucl Med. 2018;59(4):589–95.

63. Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;e-pub ahead of print.

64. Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediatinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–6.

65. Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(15):3801–9.

66. Cheson BD. Speaking volumes about volumes. Blood. 2018;131(22):2408–9.

67. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435–44.

68. Metser U, Prica A, Hodgson DC, Mozuraitis M, Eberg M, Mak V, et al. Effect of PET/CT on the management and outcomes of participants with Hodgkin and aggressive non-Hodgkin lymphoma: a multicenter registry. Radiology. 2019;290(2):488–95.

69. Ponisio MR, McConathy J, Laforest R, Khanna G. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol. 2016;46(9):1258–68.

70. Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol. 2016;3:e467–79.

71. Viviani S, Mazzocchi A, Pavoni C, Taverna F, Rossi A, Patti C, et al. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. Hematol Oncol. 2020;38(4):501–8.

72. Mokrane FZ, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, et al. Performance of CT compared with (18)F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology. 2020;295(3):651–61.

73. Lopci E, Meignan M. Current evidence on PET response assessment to immunotherapy in lymphomas. PET Clin. 2020;15(1):23–34.

74. Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, et al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLLO5 trial of the Fondazione Italiana Linfomi. Haematologica. 2016;101:e66-e8.

75. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–44.

76. Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Overall Survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018:Jco2017763656.

77. Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, et al. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia. 2020;34(2):522–32.

78. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–53.

79. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.

80. Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, et al. (18)F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40–5.

81. Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, et al. A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma. Sci Rep. 2019;9(1):1322.

82. Cheson BD. Predicting the future for DLBCL. Blood. 2020;135(16):1308–9.

83. Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, et al. Prospective study of 3'-deoxy-3'-18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57(5):728–34.

84. Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, et al. In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of (18)F-(2S,4R)-4-fluoroglutamine. Radiology. 2018;287(2):667–75.

85. Jauw YWS, O'Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven van Oordt CW, Morschhauser F, et al. (89)Zr-Immuno-PET: toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo. J Nucl Med. 2019;60(12):1825–32.

86. Barré L, Hovhannisyan N, Bodet-Milin C, Kraeber-Bodéré F, Damaj G. [(18)F]-Fludarabine for hematological malignancies. Front Med (Lausanne). 2019;6:77.

87. Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, et al. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI. Theranostics. 2019;9(12):3653–8.

88. Barrington SF, Zwezerijnen BG, de Vet HC, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful ? J Nucl Med. 2020.

89. Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2020.

90. Le Gouill S, Ghesquieres H, Obéric L, Morschhauser F, Tilly H, Ribrag V, et al. Obinutuzumab versus rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood. 2020.